Next Article in Journal
Physical Activity Associated with Public Transport Use—A Review and Modelling of Potential Benefits
Next Article in Special Issue
Using Bioinformatic Approaches to Identify Pathways Targeted by Human Leukemogens
Previous Article in Journal
First Report of a Toxic Nodularia spumigena (Nostocales/ Cyanobacteria) Bloom in Sub-Tropical Australia. II. Bioaccumulation of Nodularin in Isolated Populations of Mullet (Mugilidae)
Previous Article in Special Issue
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents
Int. J. Environ. Res. Public Health 2012, 9(7), 2444-2453; doi:10.3390/ijerph9072444
Review

Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor

Received: 16 May 2012; in revised form: 27 June 2012 / Accepted: 28 June 2012 / Published: 10 July 2012
View Full-Text   |   Download PDF [112 KB, uploaded 19 June 2014]
Abstract: Etoposide is an anticancer agent, which is successfully and extensively used in treatments for various types of cancers in children and adults. However, due to the increases in survival and overall cure rate of cancer patients, interest has arisen on the potential risk of this agent for therapy-related secondary leukemia. Topoisomerase II inhibitors, including etoposide and teniposide, frequently cause rearrangements involving the mixed lineage leukemia (MLL) gene on chromosome 11q23, which is associated with secondary leukemia. The prognosis is extremely poor for leukemias associated with rearrangements in the MLL gene, including etoposide-related secondary leukemias. It is of great importance to gain precise knowledge of the clinical aspects of these diseases and the mechanism underlying the leukemogenesis induced by this agent to ensure correct assessments of current and future therapy strategies. Here, I will review current knowledge regarding the clinical aspects of etoposide-related secondary leukemia, some probable mechanisms, and strategies for treating etoposide-induced leukemia.
Keywords: etoposide; secondary leukemia; MLL; treatment etoposide; secondary leukemia; MLL; treatment
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Ezoe, S. Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor. Int. J. Environ. Res. Public Health 2012, 9, 2444-2453.

AMA Style

Ezoe S. Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor. International Journal of Environmental Research and Public Health. 2012; 9(7):2444-2453.

Chicago/Turabian Style

Ezoe, Sachiko. 2012. "Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor." Int. J. Environ. Res. Public Health 9, no. 7: 2444-2453.


Int. J. Environ. Res. Public Health EISSN 1660-4601 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert